Somite

The development of cell therapies has historically been hindered by decade-long timelines, prohibitive costs, and extensive trial-and-error processes. This has limited the ability to quickly deliver transformative treatments for diseases ranging from metabolic disorders like type 1 diabetes to muscular diseases and blood disorders.

‍At Somite, we’re building foundation models for human stem cells to fundamentally transform how we develop novel cell therapies. Our proprietary capsule technology allows us to generate data at an unprecedented scale: 1,000 times more efficiently than current state-of-the-art methods. These proprietary data are used to train our DeltaStem foundation model, accelerating the discovery of new cell differentiation protocols and optimizing them for purity, functionality, and scalability.

‍This funding represents what we believe will lead to an AlphaFold moment for developmental biology, where advancements in AI transform our understanding of cell differentiation from a costly guessing game into a compute-bound engineering discipline. Our approach doesn’t just make the development of cell therapies faster and cheaper—it enables entirely new therapeutic possibilities by reliably producing cell types previously beyond reach. This opens the door to creating a foundry of human spare parts, enabling cures for a wide range of diseases.